# US 2021/0332126 A1 · Anti-il-6 antibodies for the treatment of oral mucositis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332126 A1
- Document ID: US20210332126A1
- Status: Published application
- Kind: A1
- Application number: 17/163,892
- Filed: 2021-02-01
- Published: 2021-10-28
- Earliest claimed: 2010-11-23
- Assignees: Vitaeris Inc.
- Applicants: Vitaeris Inc.
- Inventors: Jeffrey T.L. SMITH; Leon F. Garcia-Martinez; Andrew L. Feldhaus
- Web page: https://patentgrep.com/patent/US20210332126A1

## CPC

- C07K 16/248: {IL-6}
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/204: {IL-6}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/12: Antidiarrhoeals
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.

## Claims

### Claim at position 1

-481. (canceled)

### Claim 482

A method of treatment or prevention of graft versus host disease (GVHD) in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702.

### Claim 483

A method of treatment or prevention of transplant rejection in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702.

### Claim 484

A method of treatment or prevention of reperfusion injury in a subject in need thereof comprising administering to said subject a prophylactically or therapeutically effective amount of an anti-human interleukin-6 (IL-6) antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 704 and a light chain comprising the amino acid sequence of SEQ ID NO: 702.
